Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    Oblimersen

    go.drugbank.com/drugs/DB13811
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    1,10-Phenanthroline

    go.drugbank.com/drugs/DB02365
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    G4460

    go.drugbank.com/drugs/DB06359
    Investigational

  4. Drug

    KOS-1584

    go.drugbank.com/drugs/DB05903
    Investigational

    KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. … KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation.

  5. Drug

    Nitrazepam

    go.drugbank.com/drugs/DB01595
    Approved

    A benzodiazepine derivative used as an anticonvulsant and hypnotic.

    Synonyms: N-desmethylnimetazepamProducts: EATAN N
  6. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis. … Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent.

  7. Drug

    Sulfamethizole

    go.drugbank.com/drugs/DB00576
    ApprovedVet approved

    A sulfathiazole antibacterial agent.

  8. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)

  9. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)). … POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).